Interview: What Does Breakthrough Designation Mean For Manus Neurodynamica?
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.
You may also be interested in...
Rutger Zietsma, founder of Manus Neurodynamica and one of In Vivo's Rising Leaders of 2022, explains how his prior work guided his journey into executorship, and the issues of trust and talent in a start-up environment.
Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.
A panel of experts in the health care and medical device industries discussed the fate of the Medicare Coverage for Innovative Technology (MCIT) rule during AdvaMed’s annual Medtech Conference.